drugset / Trial / NCT02023905
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects, good and/or bad, everolimus (RAD001, also known as Afinitor®) alone or with temozolomide has on the patient and the patient's low-grade glioma. Everolimus is being investigated as an anticancer agent based on its potential to prevent tumor cells from growing and multiplying. Specifically, there is a protein called mTOR that we think helps many tumors to grow, and everolimus blocks the effect of mTOR. Temozolomide is also an anticancer agent that prevents tumor cells from growing and multiplying.
Timeline
- Start
- 2014-03-19
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | — |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | — |